Sign In
Buy AKBA
$0.84
-0.0659 (-7.24%)
At Close: Aug 10, 2026
Akebia Therapeutics, Inc. (AKBA) Q1 2025 Earnings Call Transcript
12:44pm, Thursday, 08'th May 2025
Akebia Therapeutics, Inc. (NASDAQ:AKBA ) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Mercedes Carrasco - Senior Director of Investor Relations John Butler - Chief Exec
Akebia Therapeutics (AKBA) Q1 Earnings and Revenues Top Estimates
09:21am, Thursday, 08'th May 2025
Akebia Therapeutics (AKBA) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to loss of $0.09 per share a year ago.
Akebia Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
07:00am, Thursday, 08'th May 2025
Strong initial quarter of Vafseo® (vadadustat) U.S. product launch, with Vafseo net product revenues of $12.0 million in Q1 2025 Total Q1 2025 net product revenues of $55.8 million Bolstered balance
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:15pm, Thursday, 01'st May 2025
CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,
Akebia Therapeutics (AKBA) Expected to Beat Earnings Estimates: Should You Buy?
11:07am, Thursday, 01'st May 2025
Akebia Therapeutics (AKBA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Akebia Therapeutics to Report First Quarter 2025 Financial Results and Discuss Recent Business Highlights
08:00am, Thursday, 01'st May 2025
CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the first quarter ended March 31, 2025, on Thur
Why You Shouldn't Bet Against Akebia Therapeutics (AKBA) Stock
10:00am, Thursday, 10'th Apr 2025
Akebia Therapeutics (AKBA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
CAMBRIDGE, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Wednesday, 02'nd Apr 2025
CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease
Akebia Therapeutics Announces Poster Presentations at NKF Spring Clinical Meetings 2025
08:00am, Tuesday, 25'th Mar 2025
CAMBRIDGE, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,
Akebia Stock Drops 28% on Pricing of $50M Common Stock Offering
02:05pm, Friday, 21'st Mar 2025
AKBA's shares fell after announcing the pricing of its secondary issue of shares, which were at a discount to the previous closing price.
JOYY, Akebia Therapeutics, Microchip Technology And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
08:18am, Thursday, 20'th Mar 2025
U.S. stock futures were lower this morning, with the Dow futures falling around 200 points on Thursday.
Akebia Therapeutics Announces Pricing of Public Offering of Common Stock
10:17pm, Wednesday, 19'th Mar 2025
CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (“Akebia”) (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by k
Akebia Therapeutics Announces Proposed Public Offering of Common Stock
04:01pm, Wednesday, 19'th Mar 2025
CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (“Akebia”) (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by k
Akebia Therapeutics, Inc. (AKBA) Q4 2024 Earnings Call Transcript
10:21am, Thursday, 13'th Mar 2025
Akebia Therapeutics, Inc. (NASDAQ:AKBA ) Q4 2024 Earnings Conference Call March 13, 2025 8:00 AM ET Company Participants Mercedes Carrasco - Senior Director, IR John Butler - CEO Nick Grund - Chief Co
